Simmet, V <br/><br/>
Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  11 2019 
 - 1751-1759 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdz286  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>B7-H1 Antigen--antagonists & inhibitors<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Clinical Trials, Phase I as Topic--standards<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Maximum Tolerated Dose<br/>Neoplasms--drug therapy<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors<br/>Protein Kinase Inhibitors--administration & dosage<br/>Research Design--standards<br/>Treatment Outcome